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834 The Journal of Thoracic and CardioObjective: We sought to evaluate the incidence and nature of pulmonary stenosis
after implantation of the bovine jugular vein graft (Contegra; Medtronic, Inc,
Minneapolis, Minn) in the right ventricular outflow tract.
Methods: Between May 2000 and September 2002, 58 Contegra conduits (8-22
mm) were implanted during primary (n  27) or redo operations (n  31) in 57
patients, with ages ranging from 2 days to 48 years (mean, 9 years). Indications were
truncus arteriosus (n  16), tetralogy of Fallot (n  28), pulmonary replacement in
the Ross operation (n 10), and Rastelli-type repair for double-outlet right ventricle
(n  4). Echocardiography was prospectively performed by a fixed team of
investigators during follow-up (mean, 22.7  10 months). A peak gradient of
greater than 50 mm Hg was considered severe stenosis.
Results: Two patients died from Staphylococcus aureus–induced septicemia and en-
terococcal endocarditis after 12 days and 12 weeks, respectively. One patient died of
heart failure caused by endocardial fibroelastosis after 1 year. Freedom from severe
stenosis at the distal anastomosis was 91% 3% at 3 months, 68% 6% at 12 months,
and 49% 8% at 24 months. The risk of development of stenosis does not change over
time. Younger age and its derivatives (graft size and indication) are significantly related
to the occurrence of severe stenosis (P .0001). Seventeen (29%) conduits required an
endovascular intervention (balloon dilatation or stent). Seven (12%) conduits were
explanted (endocarditis, 2; stenosis, 5). Histologic analysis of the explanted conduits
showed excessive proliferation of neointima at the level of the distal anastomosis. Valve
regurgitation was observed in 9 (16%) conduits and was always secondary to dilatation
in the presence of severe distal stenosis.
Conclusion: The Contegra conduit induces a neointimal proliferation at the level of
the pulmonary anastomosis. This leads to a high incidence of severe stenosis at
intermediate-term follow-up.
The Contegra conduit (Medtronic, Inc, Minneapolis, Minn) is a het-erologous bovine jugular vein graft with a trileaflet venous valve.The conduit is fixed with 0.6% glutaraldehyde under zero pressurecondition. No additional anticalcification treatment is used. Animaltrials showed an excellent durability and a low calcification rate.1-4Because this conduit is available in sizes between 12 and 22 mm, it
became an ideal candidate for reconstruction of the right ventricular outflow tract in
vascular Surgery ● December 2004
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Dchildren with congenital heart disease. Several groups re-
ported encouraging initial clinical results.5-9 However, the
occurrence of stenosis at the level of the distal anastomosis
was reported.10,11 We investigated our patient group to
evaluate the incidence and nature of graft stenosis after
implantation of this bovine jugular vein graft.
Methods
Patients
Between May 2000 and September 2002, 58 Contegra conduits
were implanted in 57 patients to reconstruct the right ventricular
outflow tract. Indications were truncus arteriosus (n 16), tetral-
ogy of Fallot (n  28), pulmonary replacement in the Ross
operation (n  10), and Rastelli-type repair for double-outlet right
ventricle (n  4). The conduits were placed during a primary
operation in 27 patients and during a redo operation in 31 patients.
Ages varied between 2 days and 49 years (mean, 9 years).
Surgical Technique
All implantation procedures were done during support with car-
diopulmonary bypass and moderate hypothermia. Antegrade crys-
talloid cardioplegia was used to arrest the heart. The conduits were
rinsed (3 times for 5 minutes in normal saline solution). The length
of the valve in the Contegra conduit exceeds 2 cm. Therefore the
distal part of the conduit was cut at the level of the commissures.
The proximal part of the conduit was cut with a redundant anterior
flap to construct the hood of the outflow tract. All anastomoses
were performed with running polypropylene sutures. The anatom-
ically largest graft size was used. Figure 1 shows the distribution
of graft size in relation to body surface area. In one neonate (body
surface area, 0.19 m2) the Contegra graft was bicuspidized to
reduce its size to 8 mm. Transesophageal echocardiography was
performed routinely in the operating room and allowed immediate
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Figure 1. The number of implanted graft sizes. Smaller sizes were
implanted in patients with smaller body surface areas (bsa). One
valve was bicuspidized to an 8-mm graft.evaluation of the graft.
The Journal of ThoraciFollow-up
Patients did not receive aspirin or any other antiaggregant or
anticoagulant medication. Postoperative echocardiography was
performed by a fixed team of 4 investigators. All patients had a
predischarge echocardiographic evaluation and were followed,
according to the study protocol, at 1, 3, 6, and 12 months after the
operation and yearly thereafter. In case of pathologic findings (like
an increased gradient), the patients were asked to return earlier. An
instantaneous peak gradient of greater than 50 mm Hg was con-
sidered severe stenosis. A pulmonary valve regurgitation grade 3
or 4 or more was considered significant. Grading of the pulmonary
valve insufficiency was based on the following echocardiographic
findings: a regurgitation jet restricted to the right ventricular out-
flow tract (grade 1), a jet reaching into the ventricular body (grade
2), backflow starting from the level of the pulmonary artery bifur-
cation (grade 3), and backflow starting from the peripheral pulmo-
nary artery branches (grade 4). One patient was lost to follow-up
after 1 month. The mean follow-up was 22.7  10 months.
Analysis of Data
The occurrence of pulmonary stenosis is presented with a Kaplan-
Meier survival curve with 95% confidence limits. Cox regressions
have been used to verify the relationship between different covari-
ates and pulmonary stenosis. The reported P values are obtained
with likelihood ratio tests. A Weibull model has been used to
verify the shape of the hazard function. All analyses have been
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Figure 2. Kaplan-Meier curve (95% confidence limits) of the free-
dom from severe stenosis at the distal anastomosis (peak gradi-
ent, >50 mm Hg). The hazard of development of pulmonary ste-
nosis does not decrease significantly over time.
TABLE 1. Simple Cox regression
Hazard ratio P value
Sex 0.77 .53
Diagnosis .03
Rastelli vs truncus .011
Primary operation 2.95 .009
Younger age 0.865 .0001
Smaller graft size 0.818 .0001
In a multiple regression only age or size remains significant.performed with the statistical package SAS (version 8.2).
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Patient Outcome
Two patients died from Staphylococcus aureus–induced
septicemia and enterococcal endocarditis after 12 days and
12 weeks, respectively. One patient died after 12 months of
heart failure (patient with endocardial fibroelastosis). The
Contegra graft in this patient functioned well, without ste-
nosis or valve regurgitation. Three (5%) patients were given
diagnoses of endocarditis. One died, and the 2 others were
cured through the removal of the conduit and the placement
of a homograft.
Contegra Function
All observed stenoses were located at the distal anastomo-
sis. Freedom from severe stenosis at the distal anastomosis
was 91%  3% at 3 months, 68%  6% at 12 months, and
49%  8% at 24 months (Figure 2). A Weibull model was
fitted to obtain an idea of the shape of the hazard function.
The estimated scale parameter equals 1.12 (95% confidence
limits, 0.78-1.59), which indicates that there is no evidence
for a nonconstant hazard.
Simple Cox regression indicates primary repair, younger
age, and smaller graft size as significantly related to the
occurrence of distal graft stenosis (Table 1). For the effect
of diagnosis, only the difference between truncus arteriosus
and Rastelli repair was significant. However, the group of
patients undergoing Rastelli repair was small and contained
no events. In a multiple regression framework, only age or
graft size remained significant. The correlation between
younger age and smaller graft size is very high (Spearman
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Figure 3. Kaplan-Meier curve of the freedom from severe steno-
sis at the distal anastomosis (peak gradient, >50 mm Hg) for the
small graft sizes (interrupted line) and the large graft sizes (full
line). In small sizes (graft size, <20 mm) hemodynamic gradients
develop more quickly (P  .0007). However, in the adult sizes
(graft sizes 20 and 22 mm) 15% of the patients had stenosis after
1 year.correlation,  0.89).
836 The Journal of Thoracic and Cardiovascular Surgery ● DeceAlthough graft size is significantly related to the occur-
rence of stenosis, large graft sizes also resulted in a high
incidence of stenosis. At 1 year of follow-up, 15% of
patients with an adult graft size (size 20 or 22) already had
a severe stenosis (Figure 3) at the distal anastomosis. Ste-
nosis occurred in ten of twelve 12-mm grafts, three of five
14-mm grafts, two of four 16-mm grafts, none of two
18-mm grafts, three of seven 20-mm grafts, and seven of
twenty-eight 22-mm grafts.
Seventeen (29%) conduits required an endovascular in-
tervention (balloon dilation or stent). Seven (12%) conduits
were explanted (2 because of endocarditis and 5 because of
stenosis). The 5 conduits explanted because of stenosis had
peak gradients of between 70 and 80 mm Hg, despite
balloon dilation and stenting.
Pulmonary valve regurgitation (3/4) was diagnosed in
9 (16%) patients. In all cases this was secondary to a
dilation of the conduit caused by severe distal stenosis.
Pathologic Findings
The 2 conduits explanted for endocarditis were excluded for
further analysis of the distal anastomosis. The 5 other grafts
were explanted after 12, 16, 19, 32, and 32 months, respec-
tively.
All conduits showed preserved wall integrity. The leaf-
lets were intact and pliable. Low-grade calcification was
found in the wall of 3 conduits. All distal anastomoses
showed an excessive amount of neointima composed of
spindle cells more or less parallel oriented to the luminal
surface (Figures 4 and 5). There were no inflammatory cells,
newly formed vessels, or iron-loaded macrophages (sid-
erophages). As expected, the suture holes were surrounded
by a sharply demarcated foreign-body reaction in the Con-
tegra conduit, as in the pulmonary artery.
Discussion
The reconstruction of the right ventricular outflow tract is an
essential part of the treatment of congenital heart disease.
Clearly, in the growing child several reoperations seem
inevitable to adjust the graft size. Occurrences of arrhyth-
mia, dilation of the right ventricle, or both are indications
for replacement of an insufficient outflow graft. On the basis
of the increasing performance of cardiac surgical teams,
some surgeons suggest replacing an inefficient graft to
avoid damage to the right ventricular muscle.12 The gold
standard has been set with the use of the homograft. The
reported freedom from reoperation with homografts is close
to 80% at 10 years for the adult sizes.13,14 When implanted
in neonates, 75% have to be replaced within 5 years.15,16
The Contegra graft appears to be an ideal substitute. The
valve is readily available in a wide range of sizes, and it has
a nice long conduit with superior suturing and tailoring
capacities. Since its clinical introduction in 1999, several
mber 2004
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Dgroups have adapted it with enthusiasm.5-9 Animal experi-
ments with this conduit were encouraging. Herijgers and
colleagues1 showed a well-preserved valve function and a
low calcification rate of Contegra grafts when implanted in
the pulmonary position in sheep for 5 months. Although the
graft has no specific anticalcification treatment, only mini-
mal calcification was noted. Ichikawa and coworkers2 de-
scribed excellent results in adult dogs after 1 year of im-
plantation with bovine jugular vein grafts fixed with a
hydrophilic polyepoxy compound. Scavo and associates4
implanted glutaraldehyde-preserved bovine jugular vein
grafts in 31 dogs (valved and nonvalved), with a mean
follow-up of 237 days. The grafts showed a low calcifica-
tion rate and excellent hemodynamic performance.
Earlier reports in the recent literature mentioned the
occasional problems with high-grade stenosis after implan-
tation of the Contegra graft. Boudjemline and colleagues10
reported the occurrence of an aneurysm of the right ventric-
ular outflow tract secondary to a tight stenosis of the distal
anastomosis of a Contegra graft. Kadner and coworkers11
reported the formation of stenotic membranes at the distal
anastomosis, requiring graft removal in 2 of 67 implants. In
a series of 27 implants, Brown and Darragh9 reported the
occurrence of a significant obstruction at the distal anasto-
mosis in a child 18 months after implantation. Breymann
and associates6 comment, in their report on 71 implants, on
the development of a significant gradient in 6 patients just
distal from the conduit. However, the reported medium-
term durability was equivalent to that of homografts and
Figure 4. Conduit explanted after 12 months because of severe
stenosis (elastic van Gieson staining 12.5): transverse section
through the distal anastomosis showing, from top to bottom, the
normal native architecture of the pulmonary artery, the jugular
vein graft, and, at the bottom, a thick neointima. Note the suture
holes, with some surrounding foreign-body reaction confined to
the arterial and venous walls, respectively.superior to that of xenografts.
The Journal of ThoraciWe observed an increasing rate of severe stenosis local-
ized at the level of the distal anastomosis. The hazard of
creating such a stenosis did not decrease significantly in the
observed 2 years of follow-up, suggesting a chronic trigger.
The pathologic findings in the resected specimens were
consistent. There is an excessive peel formation at the distal
anastomosis. There is no active inflammatory reaction, the
valve leaflets remain pliable, the integrity of the Contegra
graft remains intact, and there are no signs of rapid calci-
fication. This peel formation is very similar to the neointima
found in vascular grafts. Morphologically, this process
seems unrelated to a coincidental complication, such as
thrombosis or infection. An organizing thrombus would
result in granulation tissue with newly formed vessels or
with the presence of siderophages originating from the
digestion of erythrocytes. Obviously the neointima is unre-
lated to the suture itself, from which it is sharply demar-
cated.
It is logical to assume that such a peel is formed to create
a smooth inner lining of small wall irregularities. It remains
puzzling why this healing process tends to overreact in the
Contegra graft. A specific feature of this Contegra graft is its
pliability. In contrast to homografts, the Contegra graft
consists of bovine jugular vein with a more compliant wall.
Chronic movement of the Contegra wall at the level of the
anastomosis could be an ongoing local trigger for peel
formation.
The similarity with the findings of Ishizaka and cowork-
ers17 in their experience with the Shelhigh No-react (Shelhigh-
Figure 5. Detail of the neointima in a conduit explanted after 12
months because of severe stenosis (elastic van Gieson staining
50). The neointima is composed of uniformly distributed spindle
cells, without neovascularization or inflammation. Concentrically
oriented histiocytes surround the suture hole. The latter reaction
is sharply demarcated from the neointima.BioMitral, Millburn, NJ) graft is striking. After implantation of
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found mild-to-severe conduit stenosis, regurgitation, or both in
84%. The typical finding of the explanted conduits was prom-
inent intimal peel formation at the distal anastomosis without
calcification. Boudjemline and associates18 suggest that the
underlying cause of this similar phenomenon might be due to
an immunologic reaction. However, in the reported Shelhigh
graft failures, as well as in our series with the Contegra graft,
there is little histologic evidence of immunologic activity.
In contrast to other series, none of our patients received
aspirin or any other antiaggregant. Aspirin plays a protec-
tive role for the endothelium and influences neointima for-
mation.19,20 In view of our current findings, it appears
logical to routinely start aspirin therapy after the implanta-
tion of this graft.
Clearly, the peel formation quickly creates hemodynamic
disturbances in small graft sizes. However, with ongoing
follow-up, we also observed severe stenoses in our adult
Contegra sizes. At 1 year, 15% of our adult patients receiv-
ing a Contegra graft already had a significant stenosis.
These results urged us to stop the use of this graft.
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Discussion
Dr John W. Brown (Indianapolis, Ind). Before I comment on this
paper, I need to disclose that I serve on the Medtronic scientific
advisory board for cardiac valves.
I want to congratulate Dr Van Garsse, Professor Daenen, and
their colleagues for their very fine presentation and for providing
me a copy of their manuscript well in advance of this meeting. By
doing so, they gave me the opportunity to review our own expe-
rience with the Contegra graft and the results of our pulmonary
homografts during a 5-year period, during which we have placed
47 Contegra grafts. I also was able to review the 8 published
manuscripts that are in the literature for the Contegra graft.
Although several investigators have reported a small incidence
of supravalvular pulmonary stenosis with the Contegra graft, Drs
Van Garsse and Daenen’s incidence of supravalvular pulmonary
stenosis is 8- to 10-fold that of the combined experience of the rest
of the published literature.
In our 47 patients we have encountered supravalvular pulmo-
nary stenosis in 3 patients, most of which we thought was due to
technical errors on our part. In 2 of these patients, the distal
pulmonary stenosis was easily remedied by balloon angioplasty.
The third patient did not yield to balloon angioplasty, and the distal
anastomosis was patched with pericardium. All 47 patients with
Contegra grafts still have their original grafts, and no patient has a
gradient of greater than 30 mm Hg.
My review of the 8 published reports of 314 patients shows that
the incidence of supravalvular pulmonary stenosis with a gradient
of only 30 mm Hg is 6%. The 50% incidence of a gradient of
greater than 50 mm Hg is outstanding.
The mean age of your patients was 9 years versus 6 years in our
series. You did not use aspirin or anticoagulants postoperatively,
but you commonly used tissue glue on the distal anastomosis. We
have always, with both our pulmonary homografts and our Con-
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Dtegra grafts, used minidose aspirin and a short course of low-
molecular-weight heparin because all of our children have central
lines, and we know that central lines produce venous obstruction.
I would conclude that there are 3 plausible causes for the high
incidence of stenosis seen in your center and the low incidence in
our center and the rest of the centers reporting results with a
Contegra graft.
One, it has to be patient-prosthesis mismatch.
Two, there might be technical problems, either pursestringing
the distal anastomosis or the conduit is put in slightly too long, and
therefore it kinks at the distal anastomosis.
The third point is that it might well be due to the lack of
anticoagulation, which produces a thrombosis that occurs in the
early postoperative period and then blanches out and gives you the
impression that you have a neointimal peel.
You have reported your results with a Contegra graft and have
abandoned its use. My question, because you admit that the Con-
tegra is a beautiful conduit in your manuscript and that the only
problem is distal pulmonary artery stenosis, is as follows: Would
you consider either altering your surgical technique or adding a
short course of antiplatelet agents or anticoagulants rather than
resorting to a pulmonary homograft that has demonstrated limited
durability and the lack of valve function within a few months after
implantation?
Dr Van Garsse. Thank you very much for your comments.
We know that we have a high incidence of stenosis at the distal
anastomosis. Therefore we looked very closely at these stenoses,
which resulted in the findings we presented today. All the patients
presenting with a stenosis underwent an angiography, and all of
them had the stenosis really at the distal anastomosis.
We do not believe that a technical problem is the reason for
these stenoses because we perioperatively perform an echocardi-
ography, and at that time, we never see that problem. Moreover,
the hazards of stenosis development are constant; in the beginning,
we do not see stenosis, but it comes over time.
Concerning your remark on anticoagulation, we do not find any
evidence of thrombosis in the neointima according to the findings
of our pathologists. We think that pliability of the graft at the distal
anastomosis might play an important role in the development of
the distal formation of neointima.
Dr Hani K. Najm (Riyadh, Saudi Arabia). We have also used
this conduit for approximately 45 patients. We have had a similar
experience to what Dr Brown has actually mentioned—almost
identical to that seen in his series—and we found that one patient,
early in our experience, came back with peripheral pulmonary
artery stenosis, which was not present or related to the surgical
procedure (ie, was not present in the early postoperative echocar-
diography). This prompted me to think that there might be some-
thing other than the technical reasons at work.
This conduit is quite long. It is around 8 to 10 cm. It is quite
soft and pliable, and if you rinse it in the usual fashion (ie, just
putting in some washing solution in the standard rinsing tech-
nique), no solution will get inside the valved conduit, especially if
you always cut the segment before and after the valve. The valve
sits in the middle. Therefore my hypothesis is that most likely you
can leave glutaraldehyde on that valve. And when you suture that
to the pulmonary arteries, you can transfer some of that glutaral-
dehyde to the pulmonary arteries, and that could fix the site of
The Journal of Thoracianastomosis and might trigger intimal hyperplasia, which can be
the reason why you could have distal stenosis.
Since then, I have totally changed the way we rinse this
conduit. We choose the conduit right at the beginning of the
procedure. We put it in for whatever—half an hour or 45 min-
utes—until we need it. I cut it and rinse it again after I cut it to
make sure that it is thoroughly rinsed from the inside.
Was this your experience, or have you changed your techniques
of rinsing?
Dr Van Garsse. Thank you for that comment as well. Well, we
also rinse the conduit in saline solution 3 times for 5 minutes and
leave it in the saline thereafter. We rinse it in such a way that the
saline is going through the valve. We do not rinse it after cutting
the conduit. This might be a good idea.
Dr Michal A. Wojtalik (Poznan, Poland). I was one of the
main investigators of the Contegra graft in clinical study. My
experience is based on 40 cases, and the long-term follow-up is
about 5 years. We have quite the opposite experience to your
experience. Therefore we are very enthusiastic about this graft.
Still, during our study, we discussed problems that appeared in
some patients. One of them was distal pulmonary stenosis. The
rinsing process was stressed as very important. For 3 years, we just
overrinse the graft, even cutting earlier the excess of the distal part
and rinsing the crosscut too. It seems to help avoid this compli-
cation.
The second problem that we discussed was immune response
that is very likely in a foreign tissue implant. My group did the
immune study in a group of 20 patients. The results were published
in Interactive Cardiovascular and Thoracic Surgery (2003;2:273-
8). We found that there was an important difference in B-cell count
between the control group and the study group half a year after
implantation of the Contegra graft and in T-cell count after 1 year.
Therefore I think that immune response might play a role in the
development of relatively rare complications after Contegra im-
plantations. That has also been proved by few obtained specimens
from explanted conduits.
Dr Van Garsse. Thank you. This is a very interesting theory,
but we could not confirm it according to the findings of the
pathologists in our study.
Dr Carlos J. Troconis (Caracas, Venezuela). Years ago, we
had similar problems of supravalvular pulmonary stenosis at the
distal anastomosis when using bovine pericardium conduits, most
of which we thought were due to technical errors, and therefore we
modified it as we did a “fish-mouth” opening and performed an
oblique anastomosis, avoiding pursestringing, and extending it
toward the left side sometimes might prevent it from happening.
Also, we did use aspirin for long periods to avoid thrombosis,
as well as anti-inflammatory therapy to prevent chronic rejections.
Finally, I would not discourage you in your work because I
think it is a good conduit to be used.
Dr Van Garsse. Thank you.
Dr Gary K. Lofland (Kansas City, Mo). I have not used this
graft, and therefore I have no conflicts to disclose. I happen to be
rather intensely allergic to glutaraldehyde, and therefore your
study would suggest that there is a problem at the bioprosthetic
interface between the graft and the native pulmonary tissue. Years
ago, John Brown and his colleagues, in really elegant studies,
demonstrated early degeneration of homografts if they were inter-
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Dposed with Dacron, as opposed to expanded polytetrafluoroethyl-
ene.
Therefore my question is a purely hypothetical one directed at
both the authors and Dr Brown. If this bioprosthetic interface were
eliminated by interposition of a short segment of polytetrafluoro-
ethylene, which appears to be inert in these situations, could these
problems be ameliorated?
Dr Van Garsse. Well, we do not think glutaraldehyde fixation
is responsible for these distal peel formations. Our theory is that it
is because of the pliability of the graft at the distal anastomosis,
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ing an excessive neointimal proliferation.
Are you suggesting some kind of reinforcement of the distal
anastomosis?
Dr Lofland. My thought is just to eliminate that bioprosthetic
interface, and we know that problems can occur when you inter-
face materials with biologic structures. Expanded polytetrafluoro-
ethylene just seems to be relatively inert and could conceivably
stent the Contegra graft open. It is a purely hypothetical question.Dr Van Garsse. Thank you.
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